SEC EDGARJUN 121 min read$JAZZ

Patil Neena M sold $278K of JAZZ

Patil Neena M (EVP & Chief Legal Officer) sold 1,200 shares of Jazz Pharmaceuticals plc (JAZZ) at $231.83 ($0.28M total) on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Patil Neena M

Published Jun 12, 2026, 8:14 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 12, 2026, 8:20 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$JAZZ

Neutral

high confidence

Mentioned

$JAZZ

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$JAZZNeutralLow

Why it matters

The filing confirms an officer’s scheduled open-market sale; absent any new company-specific news, it mainly informs sentiment/positioning rather than fundamentals.

Market read

A confirmed insider sale under a 10b5-1 plan; likely limited trading impact unless paired with other new catalysts.

What to watch

The article lacks context on total holdings, whether other insiders traded, and whether the plan size is part of a larger scheduled program.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-12; sale executed 2026-06-10.

Background

SEC Form 4 insider transaction for Jazz Pharmaceuticals (JAZZ) filed via EDGAR.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JAZZNeutralHigh confidence

Context

Jazz Pharmaceuticals Form 4 shows EVP & Chief Legal Officer Neena M. Patil sold 1,200 shares on 2026-06-10 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The disclosure is an open-market sale by an officer under a pre-arranged Rule 10b5-1 plan, with no accompanying operational or financial catalyst in the text.

Market effects

Sector

No sector read-across; this is company-specific insider transaction reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with executives de-risking ahead of personal liquidity needs; monitor for follow-on sales or buys.

Key entities

issuer
Jazz Pharmaceuticals plc
Company whose insider transaction is disclosed on Form 4.
insider
Neena M. Patil
EVP & Chief Legal Officer who sold 1,200 shares.
trading mechanism
Rule 10b5-1 plan
Pre-arranged plan cited as the basis for the sale.

Read at source ← All news

SEP 23

$JAZZLowAI 8/10

Jazz Pharmaceuticals extends $1.9B in loans to 2033

Jazz Pharmaceuticals extended and repriced its $1.9B loan, pushing the maturity date to 2033 and reducing the interest rate by 50 basis points. The company borrowed an additional $273.3M to refinance existing debt, with the new tranche amortizing over 25 years.

stocktitan.net1 min

SEP 23

$JAZZMed

New Data Highlights the Dosing Flexibility of Low-Sodium Oxybate

Jazz Pharmaceuticals presented data at SLEEP 2026 showing Xywav's dosing flexibility for narcolepsy and idiopathic hypersomnia, with stable regimens achievable in ~42 days. Real-world data indicates 91% use twice-nightly regimens, but clinicians often customize doses. Studies also show cardiovascular benefits of low-sodium oxybate. According to Jazz, Xywav's individualized dosing can improve patient outcomes.

sleepreviewmag.com2 min

SEP 20

$JAZZHighAI 8/10

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals (JAZZ) targets $5B opportunity for zanidatamab, with oncology revenue exceeding $1B. The company expects strong adoption of the triplet regimen and sees limited near-term competition. Jazz also reported 40% growth for Zepzelca and strong early adoption for Modeyso. The company generated $824M cash in H1 and raised $1B through a convertible offering, with plans for further investments and acquisitions.

finance.yahoo.com3 min

SEP 20

$JAZZHighAI 8/10

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals (JAZZ) raised its revenue estimate for Ziihera to $3B-$5B, citing potential expansion in multiple cancer types. The company expects Ziihera to become a first-line standard of care for HER2-positive gastroesophageal adenocarcinoma. Jazz also announced pipeline expansions in epilepsy and sleep-wake disorders, including new clinical trials and formulations.

finance.yahoo.com2 min

SEP 18

$JAZZHighAI 9/10

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

Jazz Pharmaceuticals (JAZZ) acquired Actio Biosciences for $820M, with potential $500M in milestone payments, to gain control of ABS-1230, a treatment for rare childhood epilepsy. Jazz reported Q2 revenue of $1.2B, up 16% YoY, and raised 2026 guidance to $4.6B-$4.75B. The company also acquired Chimerix for $944M in 2025. ABS-1230 is in Phase 1b/2a trials, with early results showing seizure reductions. Jazz trades at ~9.5x forward earnings, offering growth potential but with clinical risks.

fool.com3 min